AMRN Amarin Corporation plc
Legal ·
The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey.
Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually.
Amarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures.
Nasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.
Each American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $19.8 million | $20.9 million |
| Net income (loss) | -$38.8 million | -$82.2 million |
| Cash from operations | $6.7 million | -$31.0 million |
| Cash and equivalents | $134.7 million | $121.0 million |
| Short-term investments | $167.9 million | $173.2 million |
Our latest story on this, dated Oct 28, 2026: "Amarin settles Hikma patent and antitrust cases over generic Vascepa". The story links the filing or release it is based on. Read the story.
Amarin Corporation plc trades under the ticker AMRN on NASDAQ.
Amarin Corporation plc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Amarin Corporation plc is 897448. Its filings are on SEC EDGAR.
380,694 shares as of 2013-02-20, per the cover page of its 10-K filed 2013-02-28.
Our directory records Amarin Corporation plc under Ireland.
Our directory classifies Amarin Corporation plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Amarin Corporation plc is US0231114044.
aibio.space lists Amarin Corporation plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Amarin Corporation plc reported a net loss of $38.8 million for the fiscal year ended Dec 31, 2025, and generated $6.7 million of cash from operations, per its annual report to the SEC.
$19.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$323.4 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.
Our latest story on Amarin Corporation, dated Oct 28, 2026: "Amarin settles Hikma patent and antitrust cases over generic Vascepa". The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey. Source.
Our latest distress story, dated Jun 24, 2025: "Amarin licenses VAZKEPA in Europe to Recordati for $25 million upfront and starts restructuring". Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually. Source.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,3.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio